EXHIBIT 43

Vito, Robert

June 19, 2007

Philadelphia, PA

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MASSACHUSETTS

IN RE: PHARMACEUTICAL : MDL NO. 1456

INDUSTRY AVERAGE WHOLESALE : CIVIL ACTION:

PRICE LITIGATION : 01-CV-12257-PBS

:

THIS DOCUMENT RELATES TO :

U.S. ex rel. Ven-A-Care of :

the Florida Keys, Inc. v. :

Abbott Laboratories, Inc. :

No. 06-CV-11337-PBS :

Videotaped deposition of ROBERT

VITO was taken, pursuant to notice, at MORGAN

LEWIS & BOCKIUS, LLP, 1701 Market Street,

Philadelphia, Pennsylvania, on Tuesday, June

19, 2007, beginning at 9:10 a.m., before M.

Kathleen Muino, Professional Shorthand

Reporter, Notary Public; Michael Hunterton,

Certified Legal Video Specialist, there being

present:

267

- 1 BY MR. TORBORG:
- 2 O. And at the out -- at the outset --
- MR. TORBORG: I want to skip that one
- 4 too. Let's go to the next two.
- 5 BY MR. TORBORG:
- O. I'd like to start off by handing you a
- 7 couple of the reports that your office did.
- 8 THE WITNESS: Thank you. Thank you.
- 9 MR. TORBORG: For the record, I've handed
- Mr. Vito copies of Exhibit Abbott 030, which is the
- June 1996 OIG report titled, Suppliers' Acquisition
- 12 Costs for Albuterol Sulfate; as well as Exhibit
- Abbott 060, which is a June 1996 OIG report titled,
- 14 A Comparison of Albuterol Sulfate Prices.
- 15 BY MR. TORBORG:
- Q. Mr. Vito, I believe you'll tell me that
- you're familiar with these reports and that they
- were prepared under -- under your direction, in
- 19 your office. Is that right?
- A. Yes, sir.
- Q. And just to try to orient ourselves to
- the reports, if we go to Exhibit Abbott 030, the

268 suppliers' acquisition --1 2 Α. Okay. -- report, to the purpose on -- under 3 the Executive Summary. In that report, you were 4 examining suppliers' acquisition costs for 5 albuterol sulfate and comparing it to Medicare 6 7 allowances; is that right? Yes, we were getting the acquisition 8 costs from suppliers and then comparing that to the 9 10 Medicare allowance. And then if we can go to the other 11 Ο. 12 report --13 Okay. Α. -- A Comparison of Albuterol Sulfate 14 Prices, if we look under the Executive Summary, 15 under Purpose, the Purpose states: To assess the 16 appropriateness of the amount Medicare allows for 17 albuterol sulfate, a prescription inhalation drug 18 used in nebulizers. 19 And then under Background, the third 20 paragraph, the report states: We surveyed 21 pharmaceutical buying groups, mail order 22

269 pharmacies, and retail pharmacy stores and compared 1 their prices for generic versions of albuterol 2 sulfate to the amount that Medicare allows. 3 Did I read that right? 5 Α. Yes. And were you involved in these two 6 Ο. 7 reports? 8 Α. Yes. Now, both of these reports have a number 9 Q. 10 and a report 94 --11 Α. Yes. -- correct? And --12 Ο. 13 Α. Yes. -- what -- what does that signify? 14 0. It's the -- when we start a job, we're 15 asked to give a -- get a CIN number, and this was 16 the number that they provided to us. Generally 17 speaking, it usually means that you started in '94; 18 however, the -- the conventions used by our office 19 did not always follow that -- that pattern. 20 Do you have any reason to believe that 21 Q. these two reports here that bear a 94 number did 22

21

22

Philadelphia, PA

270 not follow that pattern? 1 Well, they were both issued at the same 2 Α. time, and they -- they have just one digit 3 difference, the 93 and the 92, so I -- I -- I don't know exactly the time frame that we did 5 these, but I am familiar with both of them. 6 And the 94 -- I understand some -- from 7 some prior testimony in the case that there was a 8 -- a fiscal year at OIG that started, I believe, on 9 October -- or -- or November 1st. 10 11 The -- the -- the --Can you tell me about that? Like fiscal 12 Ο. 13 year 1994 would --14 Would -- would start on October 1st. Α. October 1st. Sorry, I was one month 15 off. October 1st, nineteen-ninety --16 If -- if -- if you're in 1995, it would 17 Α. start, I believe, in October of 1994, and then it 18 would end in September 30th, 1995. 19 Okay. Got it. So these reports, if the 20

convention holds, were started sometime be --

between what point and what point?

22

Philadelphia, PA

271 I -- I believe they were probably -- I 1 Α. don't -- I don't know the exact time frames on 2 I'll try to locate that. Usually I could 3 see that, if you give me a minute. Okay. 4 5 requests. Okay. The -- I don't know exactly the 6 specific time frames that -- I -- I mean, are you 7 looking at the year we did the review or -- or --8 9 When the --Ο. -- when it started? 10 Α. -- report was initiated. 11 I don't know specifically when it was 12 initiated. I do know that it was signed out in 13 June of 1996, and it probably, depending upon how 14 long it takes the process to ease through our 15 headquarters, could be anywhere from six to eight 16 months beforehand or even longer when we started 17 18 the -- the review. But the 94 in these reports, you 19 indicated, would signify what to you? 20 It -- it -- it -- it signifies the year 21 Α.

in which you started the review. At least, I mean,

272

- that's generally the way it works. Sometimes we
- could start a job now and they'll give us a number
- 3 that wouldn't say 07, it might say 06.
- So, again, generally speaking, the conventions
- 5 would be if you were starting a job, then they
- 6 would give you -- if you started in '04, they would
- 7 give you an 04 number.
- 8 O. Would it be a fair inference to conclude
- 9 that this -- these two reports were started
- sometime between October 1st, 1993 and September
- 11 30th, 1994?
- A. Not -- not -- no, not for certain on
- that, because I -- I believe -- you're referring to
- the fiscal year as it's defined by the department.
- 15 I -- I'm not sure at -- at this time that we used
- that. We might have used calendar years.
- Q. You're just not sure either way?
- 18 A. I'm not sure.
- Q. Do you recall what led OIG to perform
- these analyses on albuterol sulfate?
- MR. NEAL: I'll object to the form.
- You can answer.